Journal ArticleDOI
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
Corinne Haioun,Emmanuel Itti,Alain Rahmouni,Pauline Brice,Jean-Didier Rain,Karim Belhadj,Philippe Gaulard,Laurent Garderet,Eric Lepage,Felix Reyes,Michel Meignan +10 more
Reads0
Chats0
TLDR
Predictive value of "early PET" was observed in both the lower-risk and higher-risk groups, indicating prognostic independence from the IPI, and FDG-PET should be an early guide to first-line strategies in aggressive lymphoma.About:
This article is published in Blood.The article was published on 2005-08-15. It has received 492 citations till now. The article focuses on the topics: Aggressive lymphoma & International Prognostic Index.read more
Citations
More filters
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington,N. George Mikhaeel,Lale Kostakoglu,Michel Meignan,Martin Hutchings,Stefan P. Müeller,Lawrence H. Schwartz,Emanuele Zucca,Richard I. Fisher,Judith Trotman,Otto S. Hoekstra,Rodney J. Hicks,Michael O'Doherty,Roland Hustinx,Alberto Biggi,Bruce D. Cheson +15 more
TL;DR: This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Journal ArticleDOI
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Laurie H. Sehn,Brian R. Berry,Mukesh Chhanabhai,Catherine Fitzgerald,Karamjit Gill,Paul Hoskins,Richard Klasa,Kerry J. Savage,Tamara Shenkier,Judy Sutherland,Randy D. Gascoyne,Joseph M. Connors +11 more
TL;DR: A retrospective analysis of patients with DLBCL treated with R-CHOP to assess the value of the IPI in the era of immunochemotherapy found it to be a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials.
Journal ArticleDOI
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh,Joerg Schubert,Marita Ziepert,Rudolf Schmits,Martin Mohren,Eva Lengfelder,Marcel Reiser,Christina Nickenig,Michael R. Clemens,Norma Peter,Carsten Bokemeyer,Hartmut Eimermacher,Anthony D. Ho,Martin Hoffmann,Roland Mertelsmann,Lorenz Trümper,Leopold Balleisen,Ruediger Liersch,Bernd Metzner,Frank Hartmann,Bertram Glass,Viola Poeschel,Norbert Schmitz,Christian Ruebe,Alfred C. Feller,Markus Loeffler +25 more
TL;DR: In a multivariate analysis that used six cycles of CHOP-14 without rituximab as the reference, and adjusting for known prognostic factors, all three intensified regimens improved 3-year event- free survival and progression-free survival.
Journal ArticleDOI
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Martin Hutchings,Annika Loft,Annika Loft,Mads Hansen,Mads Hansen,Lars Møller Pedersen,Lars Møller Pedersen,Thora Buhl,Thora Buhl,Jesper Jurlander,Jesper Jurlander,Simon Buus,Simon Buus,Susanne Keiding,Susanne Keiding,Francesco d'Amore,Francesco d'Amore,Anne-Marie Boesen,Anne-Marie Boesen,Anne Kiil Berthelsen,Anne Kiil Berthelsen,Lena Specht,Lena Specht +22 more
TL;DR: For prediction of PFS, interim FDG-PET was as accurate after two cycles as later during treatment and superior to computerized tomography (CT) at all times and in regression analyses, early interimFDG- PET was stronger than established prognostic factors.
References
More filters
Journal ArticleDOI
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Bertrand Coiffier,Eric Lepage,Josette Brière,Raoul Herbrecht,Hervé Tilly,Reda Bouabdallah,Pierre Morel,Eric Van Den Neste,Gilles Salles,Philippe Gaulard,Felix Reyes,Pierre Lederlin,Christian Gisselbrecht +12 more
TL;DR: A randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma found the rate of complete response was significantly higher in the group that received CHOP plus r ituximabs than in thegroup that receivedCHOP alone.
Journal ArticleDOI
E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Jan Delabie,German Ott,H. Konrad Muller-Hermelink,Elias Campo,Rita M. Braziel,Elaine S. Jaffe,Zenggang Pan,Pedro Farinha,Lynette M. Smith,Brunangelo Falini,Alison H. Banham,Andreas Rosenwald,Louis M. Staudt,Joseph M. Connors,James O. Armitage,Wing C. Chan +19 more
TL;DR: In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray.
Journal ArticleDOI
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
Andreas Rosenwald,George E. Wright,Wing C. Chan,Wing C. Chan,Joseph M. Connors,Elias Campo,Richard I. Fisher,Randy D. Gascoyne,H. Konrad Muller-Hermelink,Erlend B. Smeland,Jena M. Giltnane,Elaine M. Hurt,Hong Zhao,Lauren Averett,Liming Yang,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Richard D. Klausner,John Powell,P L Duffey,Dan L. Longo,Timothy C. Greiner,Dennis D. Weisenburger,Warren G. Sanger,Bhavana J. Dave,James C. Lynch,Julie M. Vose,James O. Armitage,Emilio Montserrat,Armando López-Guillermo,Thomas M. Grogan,Thomas P. Miller,Michel Leblanc,German Ott,Stein Kvaløy,Jan Delabie,Harald Holte,Peter Krajci,Trond Stokke,Louis M. Staudt +40 more
TL;DR: DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma and this gene-based predictor and the international prognostic index were independent prognostic indicators.
Related Papers (5)
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E. Juweid,Sigrid Stroobants,Otto S. Hoekstra,Felix M. Mottaghy,Markus Dietlein,Ali Guermazi,Gregory A. Wiseman,Lale Kostakoglu,Klemens Scheidhauer,Andreas K. Buck,Ralph Naumann,Karoline Spaepen,Rodney J. Hicks,Wolfgang A. Weber,Sven N. Reske,Markus Schwaiger,Lawrence H. Schwartz,Josée M. Zijlstra,Barry A. Siegel,Bruce D. Cheson +19 more
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Martin Hutchings,Annika Loft,Annika Loft,Mads Hansen,Mads Hansen,Lars Møller Pedersen,Lars Møller Pedersen,Thora Buhl,Thora Buhl,Jesper Jurlander,Jesper Jurlander,Simon Buus,Simon Buus,Susanne Keiding,Susanne Keiding,Francesco d'Amore,Francesco d'Amore,Anne-Marie Boesen,Anne-Marie Boesen,Anne Kiil Berthelsen,Anne Kiil Berthelsen,Lena Specht,Lena Specht +22 more